Q32 Bio Inc (QTTB)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$8.65-1.70%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Q32 Bio Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	500,000
EPS	—	-0.301
Annual ending 2026-12-31
Revenue	—	285,714
EPS	—	-1.481
Annual ending 2027-12-31
Revenue	—	714,286
EPS	—	-2.192

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain financial runway into Q4 2027	A primary condition in Q32 Bio Inc's published investment case. The stated target is Financial runway extends to Q4 2027.	Improving	Runway falls short of Q4 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Report 36-week topline results in mid-2026	It plans to report key trial results in mid-2026.	Recovered	Topline results delayed past mid-2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Engage in strategic mergers and acquisitions	A supporting condition in Q32 Bio Inc's published investment case. The stated target is Complete strategic M&A deals by end 2026.	Improving	No meaningful M&A activity by end 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2 via May 2026 8-K filing. The company entered into a securities purchase agreement with PIPE investors to raise capital, indicating engagement in strategic capital raising possibly linked to M&A activities. No further details or financial outcomes are available yet. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.19

Unavailable → $-2.19 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$1,000,000	1 / 5
2026-07-25	Unavailable	$1,000,000	1 / 5
2026-07-26	Unavailable	$1,000,000	1 / 5
2026-07-27	Unavailable	$1,000,000	1 / 5
2026-07-28	Unavailable	$1,000,000	1 / 5
2026-07-29	Unavailable	$1,000,000	1 / 5
2026-07-30	Unavailable	$1,250,000	3 / 5
2026-07-31	Unavailable	$1,250,000	3 / 5
2026-08-01	Unavailable	$1,250,000	3 / 5
2026-08-02	Unavailable	$1,000,000	1 / 5
2026-08-03	Unavailable	$1,250,000	3 / 5
2026-08-04	Unavailable	$1,250,000	3 / 5
2026-08-05	Unavailable	$1,250,000	3 / 5
2026-08-06	Unavailable	$1,250,000	3 / 5
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	$1,000,000	1 / 5
2026-08-09	Unavailable	$1,000,000	1 / 5
2026-08-10	Unavailable	$1,000,000	1 / 5
2026-08-12	Unavailable	Unavailable	3 / 4
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	$1,000,000	3 / 5
2026-08-21	Unavailable	$1,000,000	3 / 5
2026-08-22	Unavailable	$1,000,000	3 / 5
2026-08-23	Unavailable	$1,000,000	3 / 5
2026-08-24	Unavailable	$1,000,000	3 / 5
2026-08-25	Unavailable	$1,000,000	3 / 5
2026-08-26	Unavailable	$833,333	3 / 5
2026-08-27	Unavailable	$833,333	3 / 5
2026-08-28	Unavailable	$833,333	3 / 5
2026-08-29	Unavailable	$833,333	4 / 5
2026-08-30	Unavailable	$833,333	4 / 5
2026-08-31	Unavailable	$833,333	4 / 5
2026-09-01	Unavailable	$833,333	4 / 5
2026-09-02	Unavailable	$833,333	4 / 5
2026-09-03	Unavailable	$833,333	4 / 5
2026-09-04	Unavailable	$833,333	4 / 5
2026-09-05	Unavailable	$833,333	4 / 5
2026-09-06	Unavailable	$833,333	4 / 5
2026-09-07	Unavailable	$833,333	4 / 5
2026-09-08	Unavailable	$833,333	4 / 5
2026-09-09	Unavailable	$833,333	4 / 5
2026-09-10	Unavailable	$833,333	3 / 5
2026-09-11	Unavailable	$833,333	4 / 5
2026-09-12	Unavailable	$833,333	4 / 5
2026-09-13	Unavailable	$833,333	4 / 5
2026-09-14	Unavailable	$833,333	4 / 5
2026-09-15	Unavailable	$833,333	4 / 5
2026-09-16	Unavailable	$1,000,000	4 / 5
2026-09-17	Unavailable	Unavailable	3 / 4
2026-09-18	Unavailable	Unavailable	3 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	$-2.10	$833,333	5 / 5
2026-10-01	$-2.10	$833,333	5 / 5
2026-10-02	$-2.07	$833,333	5 / 5
2026-10-03	$-2.07	$833,333	5 / 5
2026-10-04	$-2.07	$833,333	5 / 5
2026-10-05	$-2.07	$833,333	5 / 5
2026-10-06	$-2.07	$833,333	5 / 5
2026-10-07	$-2.07	$833,333	5 / 5
2026-10-08	$-2.07	$833,333	5 / 5
2026-10-09	$-2.07	$833,333	5 / 5
2026-10-10	$-2.07	$833,333	5 / 5
2026-10-11	$-2.07	$833,333	5 / 5
2026-10-12	$-2.07	$833,333	5 / 5
2026-10-13	$-2.07	$833,333	5 / 5
2026-10-14	$-2.19	$714,286	6 / 6
2026-10-15	$-2.19	$714,286	6 / 6
2026-10-16	$-2.19	$714,286	6 / 6
2026-10-17	$-2.19	$714,286	6 / 6
2026-10-18	$-2.19	$714,286	6 / 6
2026-10-19	$-2.19	$714,286	6 / 6
2026-10-20	$-2.19	$714,286	6 / 6
2026-10-21	$-2.19	$714,286	6 / 6
2026-10-22	$-2.19	$714,286	6 / 6
2026-10-23	$-2.19	$714,286	5 / 6
2026-10-24	$-2.19	$714,286	6 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	4	1
2026-06-01	4	1
2026-07-01	5	1
2026-08-01	6	0
2026-09-01	6	0
2026-10-01	7	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

JefferiesSep 28

$29.00New observation · no comparable prior

$0$15.95$31.90

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain financial runway into Q4 2027Direct metric needs a verified mapping
Report 36-week topline results in mid-2026Direct metric needs a verified mapping
Engage in strategic mergers and acquisitionsDirect metric needs a verified mapping

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.2%Typical daily move · historical

Downside history

-64.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Q32 Bio Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology business, not an established earnings compounder. Its multi-year view is intact, supported by strong recent performance and clinical progress, but losses, volatile management, and high risk keep the evidence mixed.

What's priced into Q32 Bio Inc

The valuation evidence points to QTTB being cheap versus peers, despite a modelled peer premium of 14%, so the signals are not fully aligned. The snapshot does not specify what clinical or commercial success the market assumes, and it reports no major signs of pricing fragility.

What the fundamentals likely do

Recent results have been strong, including an August earnings beat, and management reported positive 36-week SIGNAL-AA Part B results. Management remains on track to pursue a registration-directed bempikibart program in the first half of 2027, subject to regulatory discussions, while the July offering is expected to fund operations through topline Phase 3 results. Near-term execution risk remains high, with a watch-level miss concern, recent litigation, and potential sensitivity to weaker employment data.

What Q32 Bio Inc hinges on

The multi-year thesis hinges on whether clinical progress supports the planned bempikibart program and whether available funding lasts through Phase 3 results. A guidance cut would be a meaningful negative, while continued strength from major healthcare peers could support the sector backdrop. Weaker jobs data could add pressure to cyclical healthcare names.